Reckitt Heroin-Addiction Unit Review Points to Possible Sale

Reckitt Benckiser Group Plc said it will start a strategic review of its pharmaceutical unit, pointing to the possible sale of a business that analysts say could fetch at least 1.5 billion pounds ($2.4 billion).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.